CARM1 Antibodies

Histone-arginine methyltransferase CARM1 (CARM1)

Methylates (mono- and asymmetric dimethylation) that the guanidino nitrogens of arginyl residues in a number of proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited into promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 households, methylates histone H3 at'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription through chromatin remodeling.

Throughout myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. Throughout monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B.

Gene Information

Human
Gene Name:	CARM1
Uniprot:	Q86X55
Entrez:	10498

Family

Belongs to:
class I-like SAM-binding methyltransferase superfamily

Alternative Names

Carm1; coactivator-associated arginine methyltransferase 1EC 2.1.1.-; EC 2.1.1; histone-arginine methyltransferase CARM1; PRMT4; PRMT4EC 2.1.1.125; Protein arginine N-methyltransferase 4

Molecular Weight

Mass (kDA):
65.854 kDA

Genomic Context

Human
Location:	19p13.2
Sequence:	19; NC_000019.10 (10871553..10923078)

Tissue Specificity

Overexpressed in prostate adenocarcinomas and high-grade prostatic intraepithelial neoplasia.

Subcellular Localizations

Nucleus. Cytoplasm. Mainly nuclear during the G1, S and G2 phases of the cell cycle. Cytoplasmic during mitosis, after breakup of the nuclear membrane.

Diseases

• Malignant Neoplasms
• Neoplasms
• Mammary Neoplasms
• Malignant Neoplasm Of Breast
• Malignant Neoplasm Of Prostate
• Prostatic Neoplasms
• Spinal Muscular Atrophy
• Atrophy
• Cell Transformation, Neoplastic
• Muscular Atrophy
• Leukemia
• Neuromuscular Diseases
• Hypoxia

• Carcinoma
• Mammary Neoplasms, Experimental
• Adenocarcinoma
• Diabetes Mellitus
• Autoimmune Diseases
• Colorectal Neoplasms
• Inflammation

Interacting Proteins

• CEBPB
• DNAJA3
• JMJD6
• NCOA3
• NUDT21

• QKI
• SMARCC1

Pathways

• Methylation
• Histone Methylation
• Cell Cycle
• Localization
• Chromatin Remodeling
• Cell Proliferation
• Regulation Of Gene Expression
• Cell Differentiation
• Protein Methylation
• Histone Modification
• Dna Repair
• Histone Arginine Methylation
• Cell Growth

• Histone Acetylation
• Response To Stress
• Tube Development
• S Phase
• Pathogenesis
• Neural Tube Development
• Transport

PTMs

• Methylation
• Acetylation
• Phosphorylation
• Reduction
• Cleavage

• Citrullination
• Ubiquitination
• Demethylation
• Sumoylation
• Carboxylation

• Acylation

Research Areas

• Cancer
• Cellular Markers
• Transcription Factors and Regulators
• Tumor Suppressors

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CARM1

Best Uses Of The CARM1 Marker From Boster Bio

This article discusses the research primary and secondary antibodies available from Boster Bio. In addition, we discuss the company's picogram sensitivity ELISA kits and IHC-optimized polyclonal antibodies. Continue reading for more information. This article also includes information about Boster Bio's custom service, including BeNeLux delivery. These are some tips for using this marker in your research.

Boster Bio research primary and second antibodies

The use of primary and secondary antibodies for the detection of CARM1 is common in various applications. The primary antibodies are produced by the immune systems and are designed to target a specific protein. They are useful for Western blotting, immunohistochemistry, and other research processes. R&D Systems provides a large variety of primary antibodies and secondaries for a variety proteins and cytokines. These antibodies are available in multiple labeled or unlabeled forms and are validated for use in over 25 species and 15 applications.

Proteins were separated using immunoprecipitation by sodium dodecylsulfate/polyacrylamide gel electrophoresis. Equal amounts of protein were transferred onto a PVDF membrane. The membranes were then blocked in 5% skimmilk and incubated overnight @ 4°C. The membranes were then washed in TBST for 15 mins to remove secondary and primary antibodies.

The research primary and secondary antibodies used by Boster Bio are unique because of their dual labeling capability. They enable scientists to ask more questions and get more context data. This allows them to identify more molecules and cells in their samples. It also allows them to identify the effects of drugs or toxins in their environment. These antibodies' unique abilities have allowed for new drug development and clinical trials.

Its picogram sensitivity ELISA kits

Unlike other ELISA kits, Boster Bio's Picokine(tm) ELISA kits are powered by proprietary blocking and coating technologies. These technologies enable picogram-level sensitiveness with minimal background. Picokine (tm) ELISA tests have been thoroughly validated and screened to ensure reproducibility and optimal performance. Boster Bio's Picokine ELISA Kits undergo rigorous validation and testing to ensure the highest quality results.

Accuracy and reproducibility are possible only with picogram-level sensitivity. Boster Bio's picogram sensitivity ELISA kit provides quantitative data from precious samples within three hours. These ELISA kits detect picogram-levels of the target antigen, equivalent to microgram levels in Western blot. ELISA kits are also available for cytokines as well as peptides.

Its IHC-optimized, polyclonal antibodies are IHC-optimized

Although IHC antibodies are readily available, it is important to select the most appropriate ones for your specific research needs. Most of the time, antibodies are purchased based on their published literature and vendor recommendations. However, it is important for you to understand the biology of the antibody before you buy it. This is especially important in the context a investigative pathology lab.

CARM1 (a nuclear protein) has epigenetic function. This may cause ER to be absent or reduced. The expression of this protein can influence the ER status in breast carcinoma. It also has a functional role in ER-dependent tumors. CARM1 is not yet understood in breast cancer.

Boster Bio was responsible for the development of the antibody. It was then validated in the laboratory. It has a high affinity for this particular antigen. The antibody can be purchased in ELISA and IHC formats. The company is a trusted source of high-affinity prima antibodies and is highly respected by the research community. Its antibodies have undergone rigorous validation in Immunohistochemistry, Western Blotting, and ELISA. The antibody's specificity in these formats can help scientists make accurate diagnosis and improve their diagnostic procedures.

CARM1 is part of the PRMT Family and plays a crucial role in the breast cancer cell-cycle. It also interacts directly with co-activators of the nuclear receptor p160. It has been implicated with histone methylation in SRC-3, which affects the estrogen-mediated proliferation of breast cancer cells. CARM1's role is still unknown.

Optimizing the concentration and time of incubation is crucial to maximize the effectiveness of IHC. The optimal IHC scenario is one tissue block that has been fixed with 10% NBF and one that has been frozen. These blocks can be frozen to test antibodies. The freezing process also allows the antibodies to retain their antigen binding and minimizes non-specific background signal.

46% of the cohort sample were positive for ER/PR. Additional file 3: Table 2 contains details and statistical analyses of the specific samples.

CARM1 can be found in all tissues. However, it is more common in ER positive tumors than in ER negative tumors. Although statistically not significant, the latter tumors have greater nuclear and cytoplasmic localizations of CARM1, although this was not statistically significant. This suggests that cytoplasmic localization of CARM1 is correlated with increased cellular proliferation and tumor invasiveness.